LobbyingSumitomo Pharma America lobbying by quarter
Sumitomo Pharma America's latest lobbying report covers Q1 2024, at $60K. Its first report covers Q4 2022; the issues it reports most are Pharmacy.
Sumitomo Pharma America
- Latest quarter
- No record
- Q2 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $60K | 1 |
| Q1 2023 | $60K | 1 |
| Q2 2023 | $60K | 1 |
| Q3 2023 | $60K | 1 |
| Q4 2023 | $60K | 1 |
| Q1 2024 | $60K | 1 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
Policy issues the reports name
- Pharmacy6 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
Firms it paid
| Firm | ||
|---|---|---|
| King & Spalding | $360K | 6 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| SCOTT DZIENGELSKI | Rep. Murphy (PA-18): Leg. Dir. (2015-2017), Sr. Leg. Asst. (2013-2015), Leg. Asst. (2012-2013), Leg. Corr. (2011-2012), Staff Asst. (2010-2011); Energy and Commerce Committee: Staff (2015-2017) | Q1 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/04/12for Q1 2024 | King & Spalding | $60K |
| 24/01/22for Q4 2023 | King & Spalding | $60K |
| 24/01/22for Q4 2023 | King & Spalding | $60K |
| 23/10/20for Q3 2023 | King & Spalding | $60K |
| 23/07/19for Q2 2023 | King & Spalding | $60K |
| 23/04/19for Q1 2023 | King & Spalding | $60K |
| 23/01/20for Q4 2022 | King & Spalding | $60K |